iBio Inc. Stock
Price
Target price
-
-
-
-
-
?4.36
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction
iBio Inc. Stock
The community is currently still undecided about iBio Inc. with 2 Buy predictions and 0 Sell predictions.
With a target price of 4 € there is potential for a 2085.79% increase which would mean more than doubling the current price of 0.18 € for iBio Inc..
Our community identified positive and negative aspects for iBio Inc. stock for the coming years. 3 users see the criterium "Worthwhile Investment for the next years" as a plus for the iBio Inc. stock. On the other hand our users think that "Non-cyclic/Cyclic" could be a problem in the future.
iBio is a listed biotechnology company with the ticker symbol iBio that focuses on developing novel plant-based biologics and vaccines to combat infectious diseases and other medical conditions. The company leverages its proprietary expression technology to rapidly produce high-quality proteins at a commercial scale, providing a cost-effective and scalable alternative to traditional manufacturing processes. iBio has strategic collaborations with leading pharmaceutical companies and is actively exploring partnerships to advance its product pipeline and expand its reach. The company is headquartered in Bryan, Texas, and is publicly traded on the NYSE American stock exchange.
Pros and Cons of iBio Inc. in the next few years
Pros
?
G***** c******* t* c**********
?
C******** o* t** e**********
?
B****
Cons
?
S********** s********
?
M***** P*******
?
W********* I********* f** t** n*** y****
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of iBio Inc. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| iBio Inc. | - | - | - | - | - | - | - |
| Biotec Pharmacon ASA | 38.610% | -2.769% | 14.909% | -19.223% | 47.114% | -82.425% | -65.801% |
| India Globalization Capital | 5.760% | 5.839% | -2.685% | -11.043% | -13.690% | -46.485% | -84.615% |
| Larimar Therapeutics Inc. | 16.030% | -1.887% | 6.122% | -53.433% | -16.129% | 27.869% | -68.453% |
Comments
iBio, Inc. (NYSE: IBIO) had its "buy" rating re-affirmed by analysts at Chardan Capital. They now have a $5.00 price target on the stock.
Show more
Ratings data for IBIO provided by MarketBeat
iBio, Inc. (NYSE: IBIO) had its "buy" rating re-affirmed by analysts at Chardan Capital. They now have a $5.00 price target on the stock.
Show more
Ratings data for IBIO provided by MarketBeat
iBio, Inc. (NYSE: IBIO) is now covered by analysts at Brookline Capital Management. They set a "buy" rating and a $3.60 price target on the stock.
Show more
Ratings data for IBIO provided by MarketBeat
